Integrated Diagnostics Holdings plc
Integrated Diagnostics Holdings plc Fundamental Analysis
Integrated Diagnostics Holdings plc (IDGXF) shows strong financial fundamentals with a PE ratio of 23.00, profit margin of 16.00%, and ROE of 27.62%. The company generates $5.1B in annual revenue with strong year-over-year growth of 38.74%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 77.3/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze IDGXF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentIDGXF demonstrates superior asset utilization.
Valuation Score
ExcellentIDGXF trades at attractive valuation levels.
Growth Score
ModerateIDGXF shows steady but slowing expansion.
Financial Health Score
ExcellentIDGXF maintains a strong and stable balance sheet.
Profitability Score
ExcellentIDGXF achieves industry-leading margins.
Key Financial Metrics
Is IDGXF Expensive or Cheap?
P/E Ratio
IDGXF trades at 23.00 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, IDGXF's PEG of 0.02 indicates potential undervaluation.
Price to Book
The market values Integrated Diagnostics Holdings plc at 6.07 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 12.27 times EBITDA. This signals the market has high growth expectations.
How Well Does IDGXF Make Money?
Net Profit Margin
For every $100 in sales, Integrated Diagnostics Holdings plc keeps $16.00 as profit after all expenses.
Operating Margin
Core operations generate 25.24 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $27.62 in profit for every $100 of shareholder equity.
ROA
Integrated Diagnostics Holdings plc generates $11.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Integrated Diagnostics Holdings plc produces operating cash flow of $949.18M, showing steady but balanced cash generation.
Free Cash Flow
Integrated Diagnostics Holdings plc generates strong free cash flow of $767.20M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.32 in free cash annually.
FCF Yield
IDGXF converts 4.06% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
23.00
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.02
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.07
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.67
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.43
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.53
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.28
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.25
vs 25 benchmark
How IDGXF Stacks Against Its Sector Peers
| Metric | IDGXF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 23.00 | 28.45 | Better (Cheaper) |
| ROE | 27.62% | 763.00% | Weak |
| Net Margin | 16.00% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.43 | 0.34 | Weak (High Leverage) |
| Current Ratio | 1.53 | 2795.60 | Neutral |
| ROA | 11.00% | -16588.00% (disorted) | Strong |
IDGXF outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Integrated Diagnostics Holdings plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
159.65%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
113.14%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
127.33%
Industry Style: Defensive, Growth, Innovation
High Growth